Bent Frandsen
Chief Executive Officer at EXPRES2ION BIOTECH HOLDING AB
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Willem Adriaan de Jongh | M | - |
Adaptvac ApS
ExpreS2ion Biotechnologies ApS
ExpreS2ion Biotechnologies ApS BiotechnologyHealth Technology ExpreS2ion Biotechnologies ApS operates as a biotechnology company which engages in the field of protein production in Drosophila Schneider-2 cells. Its services include custom proteins and research & development reagents, process development, and feasibility studies. The company was founded by Charlotte Dyring, Martin Roland Jensen, and Willem Adriaan de Jongh in 2009 and is headquartered in Horsholm, Denmark. | 15 years |
Charlotte Dyring | M | 56 |
ExpreS2ion Biotechnologies ApS
ExpreS2ion Biotechnologies ApS BiotechnologyHealth Technology ExpreS2ion Biotechnologies ApS operates as a biotechnology company which engages in the field of protein production in Drosophila Schneider-2 cells. Its services include custom proteins and research & development reagents, process development, and feasibility studies. The company was founded by Charlotte Dyring, Martin Roland Jensen, and Willem Adriaan de Jongh in 2009 and is headquartered in Horsholm, Denmark. | 15 years |
Jakob Knudsen | M | 56 |
ExpreS2ion Biotechnologies ApS
ExpreS2ion Biotechnologies ApS BiotechnologyHealth Technology ExpreS2ion Biotechnologies ApS operates as a biotechnology company which engages in the field of protein production in Drosophila Schneider-2 cells. Its services include custom proteins and research & development reagents, process development, and feasibility studies. The company was founded by Charlotte Dyring, Martin Roland Jensen, and Willem Adriaan de Jongh in 2009 and is headquartered in Horsholm, Denmark. | 7 years |
Martin Jensen | M | 64 |
ExpreS2ion Biotechnologies ApS
ExpreS2ion Biotechnologies ApS BiotechnologyHealth Technology ExpreS2ion Biotechnologies ApS operates as a biotechnology company which engages in the field of protein production in Drosophila Schneider-2 cells. Its services include custom proteins and research & development reagents, process development, and feasibility studies. The company was founded by Charlotte Dyring, Martin Roland Jensen, and Willem Adriaan de Jongh in 2009 and is headquartered in Horsholm, Denmark. | 15 years |
Allan Rosetzsky | M | 76 |
Adaptvac ApS
ExpreS2ion Biotechnologies ApS
ExpreS2ion Biotechnologies ApS BiotechnologyHealth Technology ExpreS2ion Biotechnologies ApS operates as a biotechnology company which engages in the field of protein production in Drosophila Schneider-2 cells. Its services include custom proteins and research & development reagents, process development, and feasibility studies. The company was founded by Charlotte Dyring, Martin Roland Jensen, and Willem Adriaan de Jongh in 2009 and is headquartered in Horsholm, Denmark. | 14 years |
Gitte L. Pedersen | F | 61 |
ExpreS2ion Biotechnologies ApS
ExpreS2ion Biotechnologies ApS BiotechnologyHealth Technology ExpreS2ion Biotechnologies ApS operates as a biotechnology company which engages in the field of protein production in Drosophila Schneider-2 cells. Its services include custom proteins and research & development reagents, process development, and feasibility studies. The company was founded by Charlotte Dyring, Martin Roland Jensen, and Willem Adriaan de Jongh in 2009 and is headquartered in Horsholm, Denmark. | - |
Keith Alexander | M | 48 | 4 years | |
Karin Garre | M | 67 | 3 years | |
Sara Sande | F | 49 | 3 years | |
Farshad Guirakhoo | M | 70 | 1 years | |
Max M. Søgaard | M | - | 11 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Michael Rosenvold | M | 57 |
Copenhagen Business School
| 6 years |
Jørgen Drejer | M | 69 |
NsGene A/S
NsGene A/S Pharmaceuticals: MajorHealth Technology NsGene A/S identifies neurotrophic proteins with therapeutic effects in the nervous system. It is a biotechnology company that focuses primarily on neurodegenerative disorders. The firm provides technologies that target protein therapeutics across the blood-brain-barrier and directly to diseased nerve cells. It develops therapeutic products for multiple indications with high medical needs including Alzheimer’s disease, Parkinson's disease, deafness, neuropathic pain, epilepsy, cortico-basal degeneration, and Huntington’s disease. The company was founded by Lars Ulrik Wahlberg and Teit Eliot Johansen in 1999 and is headquartered in Ballerup, Denmark. | 13 years |
Thomas Stig Plenborg | M | 57 |
Copenhagen Business School
| 4 years |
Steen Klysner | M | - | - | |
Henrik Jeppesen | M | - |
Copenhagen Business School
| 5 years |
Jan Fredskilde Andersen | M | 57 |
Copenhagen Business School
| 6 years |
Per Toelstang | M | 58 |
Copenhagen Business School
| 7 years |
Mats Gunnar Pettersson | M | 78 |
NsGene A/S
NsGene A/S Pharmaceuticals: MajorHealth Technology NsGene A/S identifies neurotrophic proteins with therapeutic effects in the nervous system. It is a biotechnology company that focuses primarily on neurodegenerative disorders. The firm provides technologies that target protein therapeutics across the blood-brain-barrier and directly to diseased nerve cells. It develops therapeutic products for multiple indications with high medical needs including Alzheimer’s disease, Parkinson's disease, deafness, neuropathic pain, epilepsy, cortico-basal degeneration, and Huntington’s disease. The company was founded by Lars Ulrik Wahlberg and Teit Eliot Johansen in 1999 and is headquartered in Ballerup, Denmark. | 4 years |
Morten Hultberg Buchgreitz | M | 57 |
Copenhagen Business School
| 1 years |
Thomas Kirk Vilsbøll | M | 57 |
Copenhagen Business School
| 1 years |
Carsten Nielsen | M | - |
Copenhagen Business School
| 4 years |
Christian Poulsen | M | 58 |
Copenhagen Business School
| 4 years |
Stina Bjerg Nielsen | F | - |
Copenhagen Business School
| 4 years |
Søren Svendsen | M | 58 |
Copenhagen Business School
| 1 years |
Rene Spurré | M | - |
Copenhagen Business School
| 4 years |
Eske Rygaard-Hjalsted | M | - | 1 years | |
Henriette Fenger Ellekrog | F | 58 |
Copenhagen Business School
| 1 years |
Claus Due Pedersen | M | - |
Copenhagen Business School
| 4 years |
Siggi Saevarsson | M | - |
Copenhagen Business School
| 3 years |
Karsten Winther | M | - |
Copenhagen Business School
| 4 years |
Charlotte Blicher | F | - |
Copenhagen Business School
| 3 years |
Mette Thorn | M | - | 2 years | |
Eivind Hauglie-Hansen | M | - |
Copenhagen Business School
| 1 years |
Jesper Fors Holmark | M | 58 |
Copenhagen Business School
| 4 years |
Pernille Erenbjerg | F | 57 |
Copenhagen Business School
| 1 years |
Bent Moltved | M | - |
NsGene A/S
NsGene A/S Pharmaceuticals: MajorHealth Technology NsGene A/S identifies neurotrophic proteins with therapeutic effects in the nervous system. It is a biotechnology company that focuses primarily on neurodegenerative disorders. The firm provides technologies that target protein therapeutics across the blood-brain-barrier and directly to diseased nerve cells. It develops therapeutic products for multiple indications with high medical needs including Alzheimer’s disease, Parkinson's disease, deafness, neuropathic pain, epilepsy, cortico-basal degeneration, and Huntington’s disease. The company was founded by Lars Ulrik Wahlberg and Teit Eliot Johansen in 1999 and is headquartered in Ballerup, Denmark. | 12 years |
Jesper Brandgaard | M | 60 |
Copenhagen Business School
| 2 years |
Tonny Andersen | M | 59 |
Copenhagen Business School
| 4 years |
Annemette Nøhr | F | 61 |
Copenhagen Business School
| 1 years |
Thomas Videbaek | M | 63 |
Copenhagen Business School
| 4 years |
Jørgen Buus Lassen | M | 90 |
NsGene A/S
NsGene A/S Pharmaceuticals: MajorHealth Technology NsGene A/S identifies neurotrophic proteins with therapeutic effects in the nervous system. It is a biotechnology company that focuses primarily on neurodegenerative disorders. The firm provides technologies that target protein therapeutics across the blood-brain-barrier and directly to diseased nerve cells. It develops therapeutic products for multiple indications with high medical needs including Alzheimer’s disease, Parkinson's disease, deafness, neuropathic pain, epilepsy, cortico-basal degeneration, and Huntington’s disease. The company was founded by Lars Ulrik Wahlberg and Teit Eliot Johansen in 1999 and is headquartered in Ballerup, Denmark. | 9 years |
Jens Hesselberg Lund | M | 54 |
Copenhagen Business School
| 5 years |
Henrik Jeberg | M | - |
Copenhagen Business School
| 3 years |
Helle Bjerre | F | 57 |
Copenhagen Business School
| 4 years |
Rúni Hansen | M | 57 |
Copenhagen Business School
| 1 years |
Heidi Birgitte Nielsen | F | 60 |
Copenhagen Business School
| 4 years |
Philip Kusk | M | - |
NsGene A/S
NsGene A/S Pharmaceuticals: MajorHealth Technology NsGene A/S identifies neurotrophic proteins with therapeutic effects in the nervous system. It is a biotechnology company that focuses primarily on neurodegenerative disorders. The firm provides technologies that target protein therapeutics across the blood-brain-barrier and directly to diseased nerve cells. It develops therapeutic products for multiple indications with high medical needs including Alzheimer’s disease, Parkinson's disease, deafness, neuropathic pain, epilepsy, cortico-basal degeneration, and Huntington’s disease. The company was founded by Lars Ulrik Wahlberg and Teit Eliot Johansen in 1999 and is headquartered in Ballerup, Denmark. | 12 years |
Hans-Christian Olesen | M | 56 |
Copenhagen Business School
| 4 years |
Hans Peter Holst | M | 82 |
Copenhagen Business School
| 2 years |
Per Madsen | M | 56 |
Copenhagen Business School
| 1 years |
Bjarke Pålsson | M | 56 |
Copenhagen Business School
| 1 years |
Stein-Tore Nybrodahl | M | 59 |
Copenhagen Business School
| 1 years |
Mattis Ranthe | M | - | 1 years |
Statistics
Country | Connections | % of total |
---|---|---|
Denmark | 54 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Bent Frandsen
- Personal Network